ICH E6(R3) and the Reality of Patient-Centric Clinical Trials in 2026

A consequential shift has taken place in the global clinical trials ecosystem. For decades, Good Clinical Practice (GCP) has acted as the ethical and operational backbone of clinical research, defining how trials are designed, conducted and monitored. In 2025, that framework underwent its most substantial revision since its inception with the adoption of ICH E6(R3).

At face value, the update appears to signal a decisive move toward patient-centricity. There is a clear shift toward more participant-centric language, with increasing use of the term ‘participant’ to replace ‘subject’. Trial design is expected to be more inclusive, flexible and reflective of real-world patient needs and sponsors are encouraged to embed quality and safety proactively, rather than retroactively correcting errors.

However, as implementation progresses into 2026, a more complex picture is emerging. While the principles of patient-centricity are clearly embedded in the guidelines, there is currently no statistical analysis available in 2026 to prove that patient outcomes or retention rates have improved solely due to this regulatory change.

As such, it’s important to ask: Has ICH E6(R3) fundamentally changed the patient experience in clinical trials, or has it primarily reshaped the regulatory and operational framework around it?

Understanding ICH E6(R3): A Structural Reframing of GCP

ICH E6(R3) is more than an update to its predecessor, E6(R2). It represents a structural redesign of Good Clinical Practice, shifting from a prescriptive rule-based framework to a principles-driven model.

Finalised in January 2025, with implementation timelines varying across regulatory regions through 2025 and beyond, the guideline introduces a new architecture consisting of overarching principles and annexes tailored to different trial types. At its core, the revision reflects two major forces shaping modern clinical research. First, the increasing complexity of trials, including decentralised, hybrid and data-rich study designs. Second, a growing recognition that traditional models of trial delivery have not adequately served patient populations.

The response is a framework that emphasises flexibility, proportionality and quality-by-design. Rather than mandating uniform processes, sponsors are expected to tailor trial design and oversight based on risk, scientific objectives and participant needs.  This shift is often framed as enabling innovation. More importantly, it creates the conditions for a more patient-centred approach to clinical research.

Patient-centricity is not a new concept in clinical research, but ICH E6(R3) formalises it in a way that previous iterations did not. One of the most symbolic changes is the encouragement to replace the term ‘subject’ with ‘trial participant’. This change is not just semantic; it reflects a broader cultural repositioning of individuals within trials as active contributors rather than passive data sources. Beyond terminology, the guideline introduces several substantive changes designed to strengthen patient involvement and protection.

Enhanced Informed Consent and Transparency

ICH E6(R3) places greater emphasis on the informed consent process, requiring that information provided to participants is clear, relevant and proportionate to the risks involved.

There is also a stronger expectation around transparency, including trial registration and results reporting. This aligns with broader regulatory trends aimed at improving trust in clinical research and ensuring that participants understand how their data will be used.

Inclusion, Diversity and Patient Involvement in Study Design

The guideline explicitly promotes more inclusive trial design. Sponsors are encouraged to justify inclusion and exclusion criteria, with the goal of improving the generalisability of trial results and ensuring that study populations better reflect real-world patient demographics.  This is particularly relevant in areas such as rare disease, oncology and precision medicine, where narrow eligibility criteria have historically limited access.

ICH E6(R3) goes further by encouraging patient and public involvement in trial design. While not mandated, this reflects a growing expectation that trials should be designed with input from the populations they aim to serve. In practice, this can include patient advisory boards, co-design of endpoints and the incorporation of patient-reported outcomes.

Technology and Decentralisation

The guideline also supports the use of digital tools, decentralised trial elements and real-world data. These approaches have the potential to reduce patient burden by minimising site visits, enabling remote monitoring and allowing participation from geographically diverse populations.

Taken together, these changes present a compelling vision of a more accessible, inclusive and participant-focused clinical trial ecosystem.

Early Implementation: A Mixed Reality

While the principles of ICH E6(R3) are widely endorsed, its implementation in early 2026 remains uneven. Regulatory alignment has progressed, though implementation timelines vary. Major regulators including the EMA, FDA and MHRA have signalled alignment with ICH E6(R3) principles, though implementation approaches vary.  However, operational adoption is a different matter.

One of the defining characteristics of ICH E6(R3) is its shift toward a principles-based approach. While this provides flexibility, it also introduces ambiguity. Sponsors and CROs must now interpret how to operationalise concepts such as proportionality, patient-centricity and quality-by-design within their own systems. This has led to variability in implementation, particularly among organisations with differing levels of maturity and resources.

Training and Technology Adoption

The transition to E6(R3) requires significant training across sponsors, investigators and site staff. The guideline itself emphasises the importance of role-specific training to ensure compliance and participant protection.  As of early 2026, many organisations are still in the process of updating standard operating procedures, retraining staff and aligning internal systems. This lag in operational readiness has slowed the real-world impact of the guideline.

Additionally, while decentralised and technology-enabled trials are a key enabler of patient-centricity, their adoption remains inconsistent. Barriers include infrastructure limitations, regulatory uncertainty in certain regions and concerns around data quality and integrity. For patients, this means that the promised reduction in trial burden is not yet universally realised.

Areas of Progress

The most important question is whether patients themselves are experiencing tangible improvements. The answer, at this stage, is cautiously optimistic but far from definitive. These trends, which can be argued as beingregulatory already underway prior to E6(R3), appear to align with the initiative’s direction.

Informed consent processes are becoming more structured and participant-focused, with increased use of digital consent platforms and simplified documentation. There is also growing adoption of patient-reported outcomes and real-world data sources, which provide a more holistic view of patient experience. In some therapeutic areas, particularly those with strong advocacy communities, patient input is increasingly influencing trial design.

However, these improvements are not yet consistent across the industry. Patient involvement in study design remains largely optional and unevenly implemented. In many cases, engagement occurs late in the process rather than at the initial design stage.

Access and inclusivity challenges also persist. While the guideline encourages broader participation, structural barriers such as geographic location, socioeconomic status and digital access continue to limit who can participate in trials. In this sense, ICH E6(R3) has established expectations, but it has not yet resolved the underlying systemic challenges.

Potential Drawbacks

No regulatory transformation of this scale comes without trade-offs. The flexibility of ICH E6(R3) requires a higher level of expertise and judgement from sponsors and investigators. This may advantage larger organisations with more resources, potentially widening the gap between large pharmaceutical companies and smaller sponsors. For patients, this could translate into uneven access to well-designed, patient-centric trials depending on the sponsor.

There is also a risk that patient-centricity becomes a compliance exercise rather than a genuine cultural shift. Terminology may change, and patient-focused language may be incorporated into protocols, but without meaningful changes to trial design or delivery, the impact on patients remains limited.

Furthermore, the increased use of digital tools and real-world data introduces additional considerations around data privacy, consent and governance. While the guideline strengthens data oversight, the practical implementation of these safeguards remains an evolving area.

Has the Landscape Changed?

It’s too early to tell whether ICH E6(R3) has fundamentally transformed the clinical trial landscape for patients. What it has done is redefine the direction of travel. The guideline establishes a clear expectation that trials should be designed around participants, not processes. It provides the regulatory legitimacy needed to prioritise patient experience alongside scientific and operational objectives.

However, as of March 2026, the impact is more visible at the structural and regulatory level than at the patient level. And yet, it is key to disclose here that regulatory frameworks of this scale typically take several years to translate into consistent operational practice.

The Road Ahead: What Will Define Success?

The success of ICH E6(R3) will ultimately depend on how effectively its principles are implemented. For patient-centricity to move beyond rhetoric, patient involvement must occur at the earliest stages of trial design. This includes defining endpoints, shaping eligibility criteria and identifying meaningful outcomes.

Sponsors must translate the flexibility of the guideline into practical frameworks that support consistent implementation. Without clear internal standards, the variability introduced by a principles-based approach may undermine its intended benefits.

Technology will play a critical role in enabling patient-centric trials, but only if supported by robust infrastructure and clear regulatory guidance. Investment in digital tools, data systems and site capabilities will be essential. Perhaps most importantly, the industry must develop better ways to measure patient-centricity. Without clear metrics, it will be difficult to assess whether the promises of ICH E6(R3) are being realised.

Conclusion

ICH E6(R3) represents one of the most significant evolutions in Good Clinical Practice in nearly three decades. Its emphasis on patient-centricity, flexibility and quality-by-design reflects a broader shift in how clinical research is conceptualised and delivered. The vision is clear: clinical trials that are more inclusive, more accessible and more aligned with the needs of participants.

However, as implementation progresses into 2026, the reality is still catching up with that vision. The framework is in place, but the transformation is ongoing. For now, ICH E6(R3) should be understood not as a completed transition, but as the foundation for a new model of clinical research, one in which patient-centricity is not just an aspiration, but an operational reality yet to be fully realised.

About the Author

Rhys

Rhys Wallett joined The PBC Group in October 2025 as a Conference Producer, where he researches and produces life sciences meetings for clinical-stage biopharma organisations. In his role, Rhys develops targeted conference programs that bring together key stakeholders across the clinical research ecosystem, from CROs and pharmaceutical sponsors to biotech innovators and regulatory experts. His work focuses on identifying emerging trends in clinical development and translating complex industry challenges into actionable conference content that drives meaningful dialogue and collaboration within the life sciences community.